Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov;48(10):855-67.
doi: 10.1310/hpj4810-855.

Canagliflozin

Dennis J Cada  1 , Kyle T Ingram  2 , Terri L Levien  3 , Danial E Baker  4
Affiliations

Canagliflozin

Dennis J Cada et al. Hosp Pharm. 2013 Nov.

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The November 2013 monograph topics are dolutegravir, levomilnacipran, ibrutinib, serelaxin, and polynuclear iron (III)-oxyhydroxide (PA21). The DUE/MUE is on dolutegravir.

PubMed Disclaimer

References

    1. Invokana [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc; March 2013
    1. Nomura S, Sakamaki S, Hongu M, et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem. 2010;53(17):6355–6360 - PubMed
    1. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13(7):669–672 - PubMed
    1. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion [abstract]. In: Program and abstracts from the 72nd Scientific Sessions of the American Diabetes Association; June 8-12, 2102; Philadelphia, PA: Abstract 79-OR - PubMed
    1. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: Results of a randomized, placebo-controlled study [published online ahead of print February 14, 2013]. Diabetes Care. doi: 10.2337/dc12-2391. - PMC - PubMed